4 269

Cited 43 times in

Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.

DC FieldValueLanguage
dc.contributor.author김기열-
dc.contributor.author김효송-
dc.contributor.author라선영-
dc.contributor.author신상준-
dc.contributor.author안중배-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.contributor.author홍민희-
dc.date.accessioned2014-12-20T16:55:56Z-
dc.date.available2014-12-20T16:55:56Z-
dc.date.issued2011-
dc.identifier.issn0030-2414-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93652-
dc.description.abstractOBJECTIVE: We aimed to describe the efficacy and safety of sunitinib in unselected Korean advanced renal cell carcinoma (RCC) patients. PATIENTS AND METHODS: From November 2005 to August 2008, 132 histologically confirmed advanced RCC patients (100 in the global expanded access program) were enrolled. Response and toxicity were assessed regularly according to the protocol. RESULTS: Within this population, 82.6% had clear cell RCC, and 28.8% were treatment naïve. Patients received a median of 5 cycles of sunitinib (range 1-30), and the mean relative dose intensity was 82.0 ± 14.20 (SD). The progression-free survival (PFS) and overall survival rates were 8.2 and 23.1 months, respectively. For the 130 evaluable patients, the objective response rate was 34.1% (n = 45); 44.7% (n = 59) exhibited stable disease. Reasons for discontinuation were disease progression (75.0%) and toxicity (7.6%). The most frequent adverse events were thrombocytopenia (75.0%), neutropenia (70.5%), and anemia (69.7%). Low body surface area (OR = 4.2, 95% CI 1.2-13.8, p = 0.02) and previously treated status (OR = 3.1, 95% CI 1.3-7.4, p = 0.01) were highly predictive of grade 3-4 toxicities. Based on these findings, a nomogram predicting the probability of 12-month PFS was constructed, giving a concordance index of 0.675. CONCLUSIONS: Despite the different toxicity profiles, maintaining adequate dose modifications and a careful follow-up enables comparable treatment outcomes for unselected Korean advanced RCC patients-
dc.description.statementOfResponsibilityopen-
dc.format.extent395~405-
dc.relation.isPartOfOncology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAnemia/chemically induced-
dc.subject.MESHAntineoplastic Agents/administration & dosage*-
dc.subject.MESHAntineoplastic Agents/adverse effects*-
dc.subject.MESHAsian Continental Ancestry Group*-
dc.subject.MESHCarcinoma, Renal Cell/drug therapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHIndoles/administration & dosage*-
dc.subject.MESHIndoles/adverse effects*-
dc.subject.MESHKidney Neoplasms/drug therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeutropenia/chemically induced-
dc.subject.MESHNomograms-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPyrroles/administration & dosage*-
dc.subject.MESHPyrroles/adverse effects*-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRisk Factors-
dc.subject.MESHThrombocytopenia/chemically induced-
dc.subject.MESHTreatment Outcome-
dc.titleSunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorKim H.S.-
dc.contributor.googleauthorHong M.H.-
dc.contributor.googleauthorKim K.b-
dc.contributor.googleauthorShin S.-J.-
dc.contributor.googleauthorAhn J.-B.-
dc.contributor.googleauthorJeung H.C.-
dc.contributor.googleauthorChung H.C.-
dc.contributor.googleauthorKoh Y.-
dc.contributor.googleauthorLee S.-H.-
dc.contributor.googleauthorBang Y.-J.-
dc.contributor.googleauthorRha S.Y.-
dc.identifier.doi10.1159/000330361-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00337-
dc.contributor.localIdA01202-
dc.contributor.localIdA02105-
dc.contributor.localIdA02262-
dc.contributor.localIdA03773-
dc.contributor.localIdA04393-
dc.contributor.localIdA03794-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02416-
dc.identifier.pmid21829041-
dc.identifier.urlhttp://www.karger.com/Article/FullText/330361-
dc.subject.keywordRenal cell cancer-
dc.subject.keywordSunitinib-
dc.subject.keywordToxicity-
dc.contributor.alternativeNameKim, Ki Yeol-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameAhn, Joong Bae-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.alternativeNameHong, Min Hee-
dc.contributor.affiliatedAuthorKim, Ki Yeol-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorAhn, Joong Bae-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorHong, Min Hee-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsnot free-
dc.citation.volume80-
dc.citation.number5-6-
dc.citation.startPage395-
dc.citation.endPage405-
dc.identifier.bibliographicCitationOncology, Vol.80(5-6) : 395-405, 2011-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
5. Research Institutes (연구소) > Oral Cancer Research Institute (구강종양연구소) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.